Document is current
Any future updates will be listed below
-
Authors
Singh, Kavita https://orcid.org/0000-0003-4330-666X
Joshi, Awantika
Venkateshmurthy, Nikhil Srinivasapura
Rahul, Rahul
Huffman, Mark D.
Tandon, Nikhil
Prabhakaran, Dorairaj
-
Funding
Funding for this research was provided by:
Fogarty International Center (1K43TW011164)
- License Information
-
More Information
Article History
Received: 27 February 2022
Accepted: 30 April 2023
First Online: 5 June 2023
Declarations
:
: In the last 3 years, MDH has received support from the World Heart Federation through unrestricted education grants from Boehringer Ingelheim, Novartis, and Bupa and from the American Heart Association, Verily, and AstraZeneca for work unrelated to this research. MDH has also received salary support from the American Medical Association for his role as an associate editor for JAMA Cardiology. MDH has planned patents for combination therapy for the treatment of heart failure. The George Institute for Global Health has a patent, license, and has received investment funding with the intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. All other co-authors declare no conflict of interests.
: This study is approved by the Institutional Ethics Committee—Public Health Foundation of India. Reference no. TRC-IEC-382/18. Participants provided consent prior to participating in the Delphi survey.
: All authors reviewed and approved the final manuscript for submission to the Global Heart.
